Doxycycline Hyclate

Catalog No.S4163 Batch:S416306

Print

Technical Data

Formula

C22H24N2O8.1/2C2H6O.HCl.1/2H2O
Molecular Weight 512.94 CAS No. 24390-14-5
Solubility (25°C)* In vitro DMSO 100 mg/mL (194.95 mM)
Water 100 mg/mL (194.95 mM)
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Doxycycline Hyclate is a member of the tetracycline antibiotics group, and is commonly used to treat a variety of infections. It is also an inhibitor of matrix metallo-proteinases (MMP).
Targets
MMP [6]
In vitro

Doxycycline hyclate 10% (DOXY) has significant toxicity effects on osteoblast cells compared to the control group with a mean cell viability of 84%. Doxycycline hyclate 10% (DOXY) results in a significantly higher alkaline phosphatase activity (approximately 56%) than the control in osteoblasts. Doxycycline hyclate 10% (DOXY) seems to slightly altered the morphology of the osteoblasts. [1]
In vivo

Doxycycline hyclate is an effective treatment for acute E. canis infection in dogs. [2]

Doxycycline hyclate (5 mg/kg, orally) decreases the collagenase activity in corneas obtained from rabbits. Doxycycline hyclate (5 mg/kg, orally) promotes corneal reepithelialization in the rabbit alkali-burn model, a result, perhaps, of the drug's ability to inhibit excessive collagenase activity. [3]

Doxycycline hyclate results in 43% of prophylaxis in orally treated mice, in contrast, the sustained-release doxycycline hyclate completely protects mice from infection and resultant pathology. [4]

Doxycycline hyclate results in bioavailability of 70%, Cmin of 1 mg/L, Cmax of 2.3 mg/L and elimination half-life of 7 hours in calves with immature rumen function. [5]

Protocol (from reference)

Cell Assay:

[7]
  • Cell lines

    MEFs

  • Concentrations

    100 ng/ml

  • Incubation Time

    12 h

  • Method

    Cells were treated with various concentrations of drug.

Selleck's Doxycycline Hyclate has been cited by 38 publications

Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate [ Cell Res, 2023, 33(11):835-850] PubMed: 37726403
The SWI/SNF chromatin-remodeling subunit DPF2 facilitates NRF2-dependent antiinflammatory and antioxidant gene expression [ J Clin Invest, 2023, 133(13)e158419] PubMed: 37200093
14-3-3σ-NEDD4L axis promotes ubiquitination and degradation of HIF-1α in colorectal cancer [ Cell Rep, 2023, 42(8):112870] PubMed: 37494179
Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer [ Oncogene, 2023, 42(14):1072-1087] PubMed: 36774408
Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer [ Oncogene, 2023, 42(14):1072-1087] PubMed: 36774408
Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer [ Oncogene, 2023, 42(14):1072-1087] PubMed: 36774408
The Integrator complex regulates microRNA abundance through RISC loading [ Sci Adv, 2023, 9(6):eadf0597] PubMed: 36763664
The Integrator complex regulates microRNA abundance through RISC loading [ Sci Adv, 2023, 9(6):eadf0597] PubMed: 36763664
Shh and Olig2 sequentially regulate oligodendrocyte differentiation from hiPSCs for the treatment of ischemic stroke [ Theranostics, 2022, 12(7):3131-3149] PubMed: 35547747
Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons [ Cell Rep, 2022, 39(1):110643] PubMed: 35385754

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.